Reactogenicity and safety assessment of an attenuated nanovaccine against scorpion envenomation: Preclinical study.

[1]  Fangjia Lu,et al.  Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant , 2017, Journal of applied toxicology : JAT.

[2]  P. Baldrick.  Dose site reactions and related findings after vaccine administration in safety studies , 2016, Journal of applied toxicology : JAT.

[3]  F. Laraba-Djebari,et al.  Development and characterization of a new carrier for vaccine delivery based on calcium-alginate nanoparticles: Safe immunoprotective approach against scorpion envenoming. , 2016, Vaccine.

[4]  A. Sterner-Kock,et al.  Morphological characterization and immunohistochemical detection of the proinflammatory cytokines IL-1β, IL-17A, and TNF-α in lung lesions associated with contagious bovine pleuropneumonia , 2016, Tropical Animal Health and Production.

[5]  Martin Bachman,et al.  Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments. , 2015, Nanomedicine.

[6]  R. House,et al.  Preclinical Safety Assessment of a Recombinant Plague Vaccine (rF1V) , 2013, International journal of toxicology.

[7]  Karen L Wooley,et al.  Cytokines as biomarkers of nanoparticle immunotoxicity. , 2013, Chemical Society reviews.

[8]  Anthony E. Gregory,et al.  Vaccine delivery using nanoparticles , 2013, Front. Cell. Infect. Microbiol..

[9]  M. van der Burg,et al.  Anti-TNF treatment blocks the induction of T cell-dependent humoral responses , 2012, Annals of the rheumatic diseases.

[10]  R. House,et al.  Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B). , 2012, Vaccine.

[11]  E. Oviedo-Orta,et al.  Progress in understanding adjuvant immunotoxicity mechanisms. , 2011, Toxicology letters.

[12]  C. Brun-Buisson,et al.  Meta-analysis of controlled studies on immunotherapy in severe scorpion envenomation , 2011, Emergency Medicine Journal.

[13]  H. Bawaskar,et al.  Efficacy and safety of scorpion antivenom plus prazosin compared with prazosin alone for venomous scorpion (Mesobuthus tamulus) sting: randomised open label clinical trial , 2011, BMJ : British Medical Journal.

[14]  F. Tacke,et al.  Role of IL-17 and Th17 Cells in Liver Diseases , 2010, Clinical & developmental immunology.

[15]  J. Lebrón,et al.  Nonclinical safety assessment of vaccines and adjuvants. , 2010, Methods in molecular biology.

[16]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[17]  Leslie V Boyer,et al.  Antivenom for critically ill children with neurotoxicity from scorpion stings. , 2009, The New England journal of medicine.

[18]  H. Kallel,et al.  Epidemiological, clinical characteristics and outcome of severe scorpion envenomation in South Tunisia: multivariate analysis of 951 cases. , 2008, Toxicon : official journal of the International Society on Toxinology.

[19]  F. Laraba-Djebari,et al.  Pathophysiological effects of Androctonus australis hector scorpion venom: tissue damages and inflammatory response. , 2008, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[20]  Yang-Kyu Choi,et al.  Aspartate Aminotransferase (AST/GOT) and Alanine Aminotransferase (ALT/GPT) Detection Techniques , 2006, Sensors (Basel, Switzerland).

[21]  J. Lebrón,et al.  Ensuring the quality, potency and safety of vaccines during preclinical development , 2005, Expert review of vaccines.

[22]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[23]  V. Choumet,et al.  Epidemiological data, clinical admission gradation and biological quantification by ELISA of scorpion envenomations in Algeria: effect of immunotherapy. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[24]  F. Laraba-Djebari,et al.  Effect of gamma irradiation on toxicity and immunogenicity of Androctonus australis hector venom. , 2003, Canadian journal of physiology and pharmacology.

[25]  Manmohan J. Singh,et al.  Advances in vaccine adjuvants , 1999, Nature Biotechnology.

[26]  Gupta,et al.  Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.

[27]  Barry Halliwell,et al.  Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils , 1998, Nature.

[28]  H. Karoui,et al.  In vivo protection against Androctonus australis hector scorpion toxin and venom by immunization with a synthetic analog of toxin II. , 1997, Vaccine.

[29]  C. Granier,et al.  In vivo protection against scorpion toxins by liposomal immunization. , 1991, Vaccine.

[30]  N. Tryding,et al.  Recommended methods for the determination of four enzymes in blood. , 1974, Scandinavian journal of clinical and laboratory investigation.